
Keywords: ALK; anaplastic lymphoma kinase; CTLs; cytotoxic T lymphocytes; DLBCL; diffuse large B-cell lymphoma; ECOG-PS; Eastern Cooperative Oncology Group Performance Status; mAb; monoclonal antibody; NSCLC; non-small cell lung cancer; non-SQC; non-squamous cell l